The Pulmonary Vasculature in Chronic Lung Disease

This book comprehensively covers pulmonary vascular disease and its relation to lung disease. Pulmonary vascular disease is a major complication of all types of lung disease including smoking related lung disease (COPD, emphysema) and interstitial lung disease, serving as significant source of morbidity and mortality in these patients. The co-evolution of lung disease and vascular disease is a very interesting area of research activity in an attempt both to understand and seek treatments for disease of the lung as well as to risk stratify and prevent the development of pulmonary hypertension in these patients. At the same time, there is significant clinical interest in diagnosing, phenotyping and treating patients with lung disease complicated by pulmonary hypertension, in part due to several new mechanistic agents that are coming to the market for treatment of pulmonary hypertension, as well as the first ever large positive clinical trial of the treatment of pulmonary hypertensionassociated with ILD.
These chapters, written by experts in the field, bring together topics spanning the biology, pathophysiology and clinical diagnosis and treatment of pulmonary vascular disease in the context of chronic lung diseases. It also spans all major types of lung disease, dividing the topics based on pathophysiology as well as clinical phenotype. It contains within it both the latest research directions in the field for the research driven reader, but also the clinical recommendations and the pathways of likely clinical development in the field for both the treating clinicians as well as the clinical opinion leaders and directors of clinical research. 
This is an ideal guide for pulmonary physicians taking care of patients with lung disease or pulmonary hypertension, cardiologists taking care of pulmonary hypertension patients with lung disease, rheumatologists, and translational researchers in the field of lung biology and pulmonary vascular physiology.

List of contents

Introduction.- Lung endothelial cells and their heterogeneity in chronic lung diseases.- Mesenchymal vascular cells in chronic lung diseases pericytes smooth muscle cells and adventitia fibroblasts.- Platelets and thrombosis in lung disease.- Biology of extracellular matrix in pulmonary vascular pathology associated with chronic lung diseases.- Genetics and population-based risk factors for pulmonary vascular disease associated Chronic Lung Disease.- Imaging of the pulmonary vasculature and right ventricle in lung disease.- Omics and precision medicine approaches in pulmonary vascular diseases associated with chronic lung disease.- Cardiopulmonary coupling in lung disease.- The pathophysiology diagnosis and clinical impact of pulmonary hypertension in in emphysema COPD and smoking related lung disease.- Diagnosis clinical impact and treatment of pulmonary hypertension associated with interstitial lung disease).- Pulmonary hypertension associated with sarcoidosis.- The challenge of designing clinical trials in lung disease complicated by pulmonary vascular disease.- Pulmonary vascular disease associated with ARDS and post-COVID syndromes.- Pulmonary vascular disease associated with other parenchymal lung diseases post TB chronic lung disease CF LAM neurofibromatosis, Histiocytosis X.- Pulmonary vascular disease associated with hypoxemia and elevation.- Future Directions.

About the author

Farbod N. Rahaghi: Dr. Rahaghi earned his undergraduate degree in physics, masters and doctoral degrees in bioengineering, and medical degree from the University of California, San Diego. He then completed his internship and residency in internal medicine at Duke University Hospital Center before moving to Boston, where he completed a clinical fellowship in pulmonary and critical care medicine followed by a research fellowship.
Dr. Rahaghi's research focuses on topics including evaluation of investigational therapies for pulmonary arterial hypertension and the role of computed tomography in assessing pulmonary hypertension. He serves as a reviewer for the American Journal of Respiratoryand Critical Care Medicine, CHEST, Circulation, and other publications. Dr. Rahaghi is a member of the American Thoracic Society, American College of Chest Physicians, Pulmonary Vascular research Institute, and several other professional organizations.
Laszlo Farkas: Born in Budapest/Hungary, Dr. Farkas obtained his education including Medical School and Doctoral Thesis in Regensburg, Germany. After focusing on clinical training in Internal Medicine at the University Hospital of the University of Regensburg, Dr. Farkas joined Dr. Martin Kolb at McMaster University for postdoctoral research training in lung tissue and vascular injury. After a short training period at Virginia Commonwealth University, Dr. Farkas joined the Faculty in the Department of Internal Medicine, Division of Pulmonary Disease and Critical Care Medicine to establish his pulmonary vascular disease laboratory. In 2019, Dr. Farkas relocated to The Ohio State University to expand his research program.
Dr. Farkas' research program focuses on the central role that altered endothelial cell function plays in lung vascular remodelling and pulmonary hypertension. Of particular interest are molecular pathways regulating endothelial cell function, including Toll-like receptor 3. He serves as editor for Frontiers in Pediatrics, PlosONE and the International Journal of Molecular Sciences and as reviewer for many prestigious journal including the American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, Nature Cardiovascular Research, Science Advances, Journal of Clinical Investigation, Circulation and Circulation Research. Dr. Farkas is a member of the American Heart Association, the American Thoracic Society and the American Physiological Society.
Oksana Shlobin: Oksana A. Shlobin, MD, FCCP, serves as Medical Director for the Pulmonary Hypertension Program and Director of Outreach and Education for the Inova Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital. She is also an Associate Professor of Medical Education at the University of Virginia. Dr. Shlobin is board certified in pulmonary and critical care medicine. Dr. Shlobin has been actively involved in clinicalresearch both during her fellowship and her tenure at Inova. She is co-author of multiple publications, including original research manuscripts, abstracts and book chapters. Her research interests include pulmonary hypertension and interstitial lung diseases.

Summary

This book comprehensively covers pulmonary vascular disease and its relation to lung disease. Pulmonary vascular disease is a major complication of all types of lung disease including smoking related lung disease (COPD, emphysema) and interstitial lung disease, serving as significant source of morbidity and mortality in these patients. The co-evolution of lung disease and vascular disease is a very interesting area of research activity in an attempt both to understand and seek treatments for disease of the lung as well as to risk stratify and prevent the development of pulmonary hypertension in these patients. At the same time, there is significant clinical interest in diagnosing, phenotyping and treating patients with lung disease complicated by pulmonary hypertension, in part due to several new mechanistic agents that are coming to the market for treatment of pulmonary hypertension, as well as the first ever large positive clinical trial of the treatment of pulmonary hypertensionassociated with ILD.
These chapters, written by experts in the field, bring together topics spanning the biology, pathophysiology and clinical diagnosis and treatment of pulmonary vascular disease in the context of chronic lung diseases. It also spans all major types of lung disease, dividing the topics based on pathophysiology as well as clinical phenotype. It contains within it both the latest research directions in the field for the research driven reader, but also the clinical recommendations and the pathways of likely clinical development in the field for both the treating clinicians as well as the clinical opinion leaders and directors of clinical research. 
This is an ideal guide for pulmonary physicians taking care of patients with lung disease or pulmonary hypertension, cardiologists taking care of pulmonary hypertension patients with lung disease, rheumatologists, and translational researchers in the field of lung biology and pulmonary vascular physiology.

Product details

• Assisted by: Oksana A Shlobin (Editor), Laszlo Farkas (Editor), Farbod N. Rahaghi (Editor), Oksana A. Shlobin (Editor)
• Publisher: Springer, Berlin
• Languages: English
• Product format: Hardback
• Release: 08.11.2025
• EAN: 9783032035806
• ISBN: 978-3-0-3203580-6
• No. of pages: 350
• Illustrations: Approx. 350 p. 90 illus., 30 illus. in color.
• Series: Respiratory Medicine
• Subjects: Natural sciences, medicine, IT, technology > Medicine > Clinical medicine; Kardiologie, Angiologie, Cardiology, Pneumology, Interstitial lung disease, Pulmonary Hypertension, ILD, pulmonary vascular disease, chronic lung disease, pulmonary vasculature